Masaki Mogi Selected Research

Neurodegenerative Diseases (Neurodegenerative Disease)

1/2013	Effect of angiotensin II type 2 receptor on stroke, cognitive impairment and neurodegenerative diseases.
4/2009	[New insights of ARB in central nervous system].

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Masaki Mogi Research Topics

Disease

25	Cognitive Dysfunction 04/2020 - 07/2006
21	Hypertension (High Blood Pressure) 01/2022 - 04/2004
19	Stroke (Strokes) 01/2022 - 11/2006
14	Vascular Remodeling 01/2020 - 02/2006
12	Inflammation (Inflammations) 04/2018 - 04/2006
11	Insulin Resistance 05/2022 - 09/2005
11	Vascular System Injuries 01/2020 - 09/2005
10	Atherosclerosis 01/2020 - 04/2005
9	Brain Ischemia (Cerebral Ischemia) 11/2015 - 09/2006
8	Dementia (Dementias) 04/2020 - 09/2009
8	Alzheimer Disease (Alzheimer's Disease) 01/2017 - 10/2008
7	Body Weight (Weight, Body) 05/2022 - 07/2009
5	Neointima 01/2020 - 11/2012
5	Cardiomegaly (Heart Hypertrophy) 01/2016 - 10/2006
5	Type 2 Diabetes Mellitus (MODY) 12/2015 - 02/2008
5	Diabetes Mellitus 05/2013 - 04/2004
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2012 - 04/2004
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 06/2011 - 07/2006
3	Muscle Weakness 01/2021 - 01/2019
3	Anaphylaxis (Anaphylactic Shock) 01/2021 - 07/2020
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 07/2002
3	Brain Injuries (Brain Injury) 10/2018 - 09/2008
3	Obesity 01/2016 - 04/2004
3	Glucose Intolerance 08/2009 - 12/2006
2	Vascular Diseases (Vascular Disease) 02/2021 - 01/2020
2	Chronic Renal Insufficiency 01/2021 - 09/2016
2	Neurologic Manifestations (Neurological Manifestations) 10/2018 - 11/2006
2	Fetal Growth Retardation (Intrauterine Growth Retardation) 03/2018 - 01/2016
2	Ischemia 11/2015 - 09/2008
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2013 - 04/2009
2	Multiple Sclerosis 01/2013 - 04/2009
2	Cerebrovascular Disorders (Cerebrovascular Occlusion) 03/2010 - 09/2009

Drug/Important Bio-Agent (IBA)

25	Angiotensin IIIBA 01/2021 - 04/2005
19	Type 2 Angiotensin ReceptorIBA 01/2019 - 09/2005
12	Glucose (Dextrose)FDA LinkGeneric 05/2022 - 12/2004
11	olmesartanIBA 11/2011 - 04/2005
10	compound 21IBA 10/2018 - 01/2012
9	Proteins (Proteins, Gene)FDA Link 04/2018 - 12/2004
8	Insulin (Novolin)FDA Link 01/2022 - 02/2006
8	AngiotensinsIBA 01/2018 - 10/2006
8	Polyethylene (Polythene)IBA 01/2016 - 09/2005
8	Type 1 Angiotensin ReceptorIBA 03/2014 - 10/2006
7	Antihypertensive Agents (Antihypertensives)IBA 01/2022 - 02/2009
7	Superoxides (Superoxide)IBA 04/2020 - 10/2006
7	ApolipoproteinsIBA 02/2008 - 04/2005
6	Angiotensin Receptor AntagonistsIBA 10/2020 - 12/2006
6	Telmisartan (Micardis)FDA Link 05/2012 - 01/2008
5	Biomarkers (Surrogate Marker)IBA 12/2019 - 12/2004
5	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2019 - 01/2012
5	PPAR gammaIBA 10/2018 - 10/2008
5	Messenger RNA (mRNA)IBA 01/2016 - 07/2006
5	Angiotensin II Type 1 Receptor BlockersIBA 05/2012 - 12/2006
5	Valsartan (Vals)FDA Link 05/2011 - 09/2005
5	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 02/2009 - 10/2006
4	SaltsIBA 01/2022 - 12/2007
4	AngiotensinogenIBA 01/2021 - 02/2009
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 10/2020 - 01/2013
4	Amyloid (Amyloid Fibrils)IBA 04/2020 - 02/2012
4	Angiotensin-Converting Enzyme 2IBA 01/2020 - 11/2011
4	2-chloro-5-nitrobenzanilideIBA 10/2018 - 10/2008
4	CytokinesIBA 04/2018 - 01/2015
4	ReninIBA 05/2011 - 02/2009
3	CholesterolIBA 05/2022 - 12/2007
3	MicroRNAs (MicroRNA)IBA 02/2021 - 01/2019
3	GTP-Binding Proteins (G-Protein)IBA 01/2021 - 04/2004
3	Rocuronium (Zemuron)FDA LinkGeneric 01/2021 - 07/2020
3	angiotensin I (1-7)IBA 01/2020 - 03/2014
3	EnzymesIBA 01/2018 - 10/2014
3	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2016 - 11/2012
3	Nifedipine (Adalat)FDA LinkGeneric 08/2010 - 11/2007
3	CalciumIBA 02/2009 - 07/2002
3	azelnidipineIBA 12/2006 - 07/2005
2	Mineralocorticoid Receptors (Mineralocorticoid Receptor)IBA 01/2022 - 09/2013
2	Pharmaceutical PreparationsIBA 01/2022 - 09/2016
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 10/2020 - 01/2017
2	Monocyte Chemoattractant ProteinsIBA 04/2020 - 11/2007
2	NADP (NADPH)IBA 04/2020 - 10/2018
2	NADPH Oxidases (NAD(P)H oxidase)IBA 04/2020 - 10/2006
2	RNA (Ribonucleic Acid)IBA 01/2020 - 02/2002
2	Interferon Regulatory Factor-1 (Interferon Regulatory Factor 1)IBA 10/2018 - 10/2016
2	salicylhydroxamic acid (SHAM)IBA 01/2018 - 11/2015
2	Rosuvastatin Calcium (Crestor)FDA Link 01/2016 - 11/2012
2	LipidsIBA 01/2016 - 06/2006
2	azilsartanIBA 04/2015 - 07/2014
2	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 01/2015 - 11/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2015 - 09/2005
2	Biological ProductsIBA 09/2013 - 03/2005
2	AldosteroneIBA 09/2013 - 04/2006
2	propagermanium (Ge 132)IBA 11/2012 - 06/2011
2	DNA (Deoxyribonucleic Acid)IBA 01/2012 - 11/2007
2	Losartan (Cozaar)FDA LinkGeneric 08/2010 - 10/2008
2	p38 Mitogen-Activated Protein KinasesIBA 05/2010 - 10/2008
2	Amyloid beta-PeptidesIBA 10/2009 - 09/2009
2	candesartanIBA 12/2007 - 09/2006
2	Eplerenone (Inspra)FDA LinkGeneric 07/2007 - 04/2006
2	Amlodipine (Norvasc)FDA LinkGeneric 11/2006 - 06/2006
2	Apolipoproteins E (ApoE)IBA 11/2006 - 09/2005
2	L-Type Calcium Channels (Dihydropyridine Receptor)IBA 11/2006 - 06/2006

Therapy/Procedure

2	Therapeutics 01/2022 - 07/2005
2	Oral Administration 01/2017 - 12/2007